Compare INVH & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INVH | NBIX |
|---|---|---|
| Founded | 2012 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 15.5B |
| IPO Year | 2016 | 1996 |
| Metric | INVH | NBIX |
|---|---|---|
| Price | $30.11 | $152.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 22 |
| Target Price | $32.50 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 3.8M | 1.4M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | 29.73 | ★ 41.95 |
| EPS | 0.63 | ★ 3.30 |
| Revenue | ★ $2,729,296,000.00 | $161,626,000.00 |
| Revenue This Year | $2.92 | $24.73 |
| Revenue Next Year | $2.43 | $13.14 |
| P/E Ratio | $48.05 | ★ $46.34 |
| Revenue Growth | 4.21 | ★ 977.51 |
| 52 Week Low | $24.25 | $122.14 |
| 52 Week High | $31.38 | $186.12 |
| Indicator | INVH | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 37.25 |
| Support Level | $29.36 | $152.67 |
| Resistance Level | $30.12 | $161.29 |
| Average True Range (ATR) | 0.42 | 4.10 |
| MACD | -0.01 | -1.08 |
| Stochastic Oscillator | 43.60 | 21.47 |
Invitation Homes owns a portfolio of over 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 17 target markets that feature high employment and household formation growth with over 70% of the portfolio in the Western US and Florida; 15 of the 17 markets featuring average rents lower than homeownership costs.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.